Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Serotonin Syndrome

• Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
• Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
• Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
• Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
• Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
• Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
• Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
• Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
• AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm
• Telotristat Etiprate for Carcinoid Syndrome Therapy
• Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
• An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
• P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
• TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
• Study of Panitumumab in the Treatment of Carcinoid Syndrome
• Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
• Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
• Azilect + Antidepressant Chart Review
• Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
• Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
• An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
• Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
• Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome